[Prognosis value of the immunohistochemical expresion of the bcl-2 in the larynx epidermoid cancer].
In this paper we carried out an immunohistochemical study of bcl-2 protein expression in a series of 195 patients with laryngeal carcinoma that were diagnosticated, treated and followed at the Department of Otolaryngology at "Virgen de la Salud" Hospital (Toledo, Spain). In the cases with lymphonode metastasis we also analysed bcl-2 protein expression at this level. Furthermore we have studied the value of bcl-2 protein expression as a prognostic factor (tumor recurrence, deads due to cancer and survival) and we analysed the relationship between bcl-2 protein expression and other clinic and pathologic parameters.
García Lozano
M C
MC
Servicio ORL, Hospital Gutiérrez Ortega, Valdepeñas. cjangela@castillalamancha.es
Orradre Romero
J L
JL
Caro García
M
M
Sáez del Castillo
A I
AI
Galán Morales
J T
JT
Piris Pinilla
M A
MA
D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000276:immunology / Q000378:metabolism*; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000276:immunology / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000276:immunology* / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53